CClinicalTrials.gg
CompletedNCT03369652Updated Mar 19, 2019

Telephone Contact Between Hospital and General Practitioner About Medication Review for Older Patients

An interventional study of Medication review in Older Patients, Medication Review and Cross-sectional Communication, sponsored by Odense University Hospital. Completed at 2 sites in Denmark. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2019-03-19.

Sponsored by Odense University Hospital · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
232
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

In this trial, the feasibility of cooperation between clinical pharmacists and physicians by conducting a telephone follow-up conversation between the hospital geriatrician, the general practitioner and the clinical pharmacist is evaluated. During hospital stay the clinical pharmacist and the geriatrician will review older patients' medication and discuss the future treatment with the general practitioner after discharge by telephone or medico-technology.

The first part of the feasibility study will be a qualitative baseline measure of characteristics of the participants and work flow. The second part will be a pilot randomized controlled study where participants will be allocated to either usual care or medication review and follow up contact

02

Conditions studied

  • Older Patients
  • Medication Review
  • Cross-sectional Communication
03

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

* 5 drugs or more

Exclusion criteria

Exclusion Criteria:

  • Terminal illness
  • Not able to speak and understand Danish
04

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
232 participants (actual)

Study arms

  • Experimental
    Intervention

    Medication history by pharmaconomist. Medication review by pharmacist, patient interview, and conference with physician in hospital, telephone contact to general practitioner after discharge, medication report sent to primary care.

    Behavioral: Medication review

  • No intervention
    Control

    Medication history by pharmaconomist. Usual care by physicians.

Interventions

  • BehavioralMedication review

    Conducted by the pharmacist and discussed with hospital physician

05

What researchers measure

Primary outcomes

  1. Changes in number of medications

    Increase or decrease in number of medications from admission to discharge

    Time frame: At admission and at discharge

  2. Parts of the intervention completed

    In the intervention Group only, it is measured, how many of the elements of the intervention the patient actually have received

    Time frame: Day 1 after discharge

  3. Changes in the Electronic Medication Profile (FMK)

    How many changes have been Applied to the Electronic Medication Profile

    Time frame: 14 days after discharge

Secondary outcomes

  1. Number of readmissions

    Data from registers

    Time frame: within 30 days after discharge

  2. Number of emergency visits

    Data from registers

    Time frame: within 30 days after discharge

  3. Number of visits at general practitioner

    Data from registers

    Time frame: within 30 days after discharge

  4. Patient satisfaction with the discharge

    Measured by telephone interview

    Time frame: 14 days after discharge

  5. Changes in patient-experienced quality of life

    Measured by telephone interview using the 5-item questionnaire EQ-5D, where each question can be answered on a 5-point Likert Scale ranging from "very high degree of problems" to "very low degree of problems"

    Time frame: At admission and 14 days after discharge

  6. Health care professionals satisfaction

    Measured by a questionnaire

    Time frame: 3 months after implementation

06

Study locations

2 sites
  • Odense University Hospital
    Odense, 5000, Denmark
  • Svendborg Sygehus
    Svendborg, Denmark
07

References and documents

Individual participant data

Plan to share: No — No IPD are planned sharing

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03369652
Lead sponsor
Odense University Hospital
Responsible party
Lene V. Ravn-Nielsen (Pharmacist, Odense University Hospital) — Principal investigator
First posted
Dec 12, 2017
Start date
Nov 24, 2017
Primary completion
Nov 1, 2018
Completion
Nov 30, 2018
Last update
Mar 19, 2019

Study contacts

Anton Pottegård, phd
study chair · University of Southern Denmark

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion